• The capacity expansion in Bubendorf reached another important milestone with the inspection of Building K. The announced start-up is proceeding according to plan.
• In Vista, CA, Bachem acquired a property adjacent to its existing facility. The acquisition will enable a future capacity expansion at the Vista site, thereby strengthening Bachem’s presence in the US market.
Bubendorf, Switzerland--(Newsfile Corp. - October 23, 2025) - Bachem, a leading partner in peptide and oligonucleotide manufacturing, today announced progress in its plans to expand capacity.
In Bubendorf, Building K was inspected by the local regulatory authorities (RHI). Based on feedback from the authorities, no delay is expected with regard to the previously communicated development plan for Building K. Bachem continues to expect that production of the first GMP batches can begin in 2025. While the commercial production in the inspected part will be ramped up in 2026, construction work in the remaining part of the building will continue.
In Vista, Bachem acquired a property adjacent to its existing facility to add additional upstream and downstream capacity in the future. Bachem will transform the existing property into a production facility. Overall, Bachem plans to invest around USD 250 million over the years 2026 - 2030 in the United States to expand the capacity in Vista and to modernize the Torrance facility.
Thomas Meier, CEO of Bachem, commented: “I’m very pleased with the progress we are making at Bachem with our capacity expansions. We are right on schedule with Building K, which is not only the largest project for Bachem, but also one of the most modern peptide production facilities in the world. Around 350 employees will produce several tons of peptides every year, which will make a significant contribution to healthcare worldwide. In addition, the new property in Vista will enable us to secure additional capacity in the United States, the world’s largest healthcare market and thus will enhance Bachem’s commercial alliances in the Unites States.”
About Bachem
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange. For further information, see www.bachem.com.
For more information:
Bachem Holding AG
Barbora Blaha
Head of Group Communication
Tel.: +41 58 595 2021
Media: media@bachem.com
Investors: ir@bachem.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/271589
In Bubendorf, Building K was inspected by the local regulatory authorities (RHI). Based on feedback from the authorities, no delay is expected with regard to the previously communicated development plan for Building K. Bachem continues to expect that production of the first GMP batches can begin in 2025. While the commercial production in the inspected part will be ramped up in 2026, construction work in the remaining part of the building will continue.
In Vista, Bachem acquired a property adjacent to its existing facility to add additional upstream and downstream capacity in the future. Bachem will transform the existing property into a production facility. Overall, Bachem plans to invest around USD 250 million over the years 2026 - 2030 in the United States to expand the capacity in Vista and to modernize the Torrance facility.
Thomas Meier, CEO of Bachem, commented: “I’m very pleased with the progress we are making at Bachem with our capacity expansions. We are right on schedule with Building K, which is not only the largest project for Bachem, but also one of the most modern peptide production facilities in the world. Around 350 employees will produce several tons of peptides every year, which will make a significant contribution to healthcare worldwide. In addition, the new property in Vista will enable us to secure additional capacity in the United States, the world’s largest healthcare market and thus will enhance Bachem’s commercial alliances in the Unites States.”
About Bachem
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange. For further information, see www.bachem.com.
For more information:
Bachem Holding AG
Barbora Blaha
Head of Group Communication
Tel.: +41 58 595 2021
Media: media@bachem.com
Investors: ir@bachem.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/271589
